首頁 > 市場調查報告書 > 製藥

疼痛

鴉片類藥物使用障礙市場規模、佔有率和成長分析（按治療方法、給藥途徑、分銷管道、最終用戶和地區分類）—2025-2032年產業預測

市場調查報告書

商品編碼

1865293

鴉片類藥物使用障礙市場規模、佔有率和成長分析（按治療方法、給藥途徑、分銷管道、最終用戶和地區分類）—2025-2032年產業預測

Opioid Use Disorder Market Size, Share, and Growth Analysis, By Treatment (Methadone, Buprenorphine), By Route of Administration (Oral, Injectable / Implant), By Distribution Channel, By End-User, By Region - Industry Forecast 2025-2032

出版日期: 2025年11月05日 | 出版商:

SkyQuest | 英文 175 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2023 年，全球鴉片類藥物使用障礙市場規模將達到 51 億美元，到 2024 年將達到 57 億美元，到 2032 年將達到 139.2 億美元，在預測期（2025-2032 年）內複合年成長率為 11.8%。

藥物濫用趨勢的上升，以及政府旨在提高公眾對鴉片類藥物使用障礙（OUD）認知的各項舉措，正顯著推動OUD治療市場的蓬勃發展。處方鴉片類藥物、海洛因和合成鴉片類藥物濫用率的不斷攀升，凸顯了有效治療方案的緊迫性。政府和公共衛生機構對OUD的日益重視，為市場長期擴張創造了機會。公眾、醫療專業人員和相關人員對OUD認知的不斷提高，也進一步推動了這一成長趨勢。此外，治療中心、門診診所、遠端醫療服務和綜合護理計畫的基礎設施改善，提高了OUD治療的可近性，並促進了收入成長。然而，社會污名、發展中地區醫療資源匱乏、治療費用高昂以及監管複雜性等挑戰，都可能阻礙未來的市場滲透。

全球鴉片類藥物使用疾患市場促進因素

全球鴉片類藥物使用障礙市場正因研發投入的不斷增加而顯著成長，這些投入主要集中在新型藥物療法上。資金的湧入促成了創新製劑的研發，這些製劑能夠有效應對各種鴉片類藥物使用障礙。值得關注的進展包括緩釋性Buprenornhine注射劑、植入、新型逆轉劑（如納曲酮）以及增強療效的聯合治療。此外，這些先進的藥物製劑能夠減少給藥頻率，進而提高患者的治療順從性。所有這些因素共同為鴉片類藥物使用障礙市場的相關人員創造了充滿希望的機會。

全球鴉片類藥物使用疾患市場的限制因素

由於社會上對鴉片類藥物使用障礙的持續污名化，全球鴉片類藥物使用障礙市場面臨嚴峻挑戰。許多患者因害怕受到批評、歧視和法律制裁而猶豫是否尋求適當的治療方法。即使有效的治療服務已經存在，由於文化和社會障礙以及患者內心深處的羞恥感，實際接受治療的比例往往低於預期。這些因素阻礙了市場的發展和擴張，因為潛在患者無法獲得所需的護理和支持，從而影響了整個行業的成長和發展。

全球鴉片類藥物使用疾患市場趨勢

全球鴉片類藥物使用障礙市場正經歷著向長效和緩釋性藥物的顯著轉變，這主要受對有效治療方法需求不斷成長的驅動。這一趨勢包括Buprenornhine注射劑、納曲酮植入劑和創新聯合療法的日益普及，這些藥物因其更高的療效和安全性而逐漸被臨床醫生接受。這些先進治療方法也越來越受到患者的青睞，因為它們能夠提高治療順從性並降低復發率，進一步凸顯了其重要性。這種不斷變化的市場模式反映了人們正努力透過更永續、更有效率的治療方法來解決鴉片類藥物使用障礙問題。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2024 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2024 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2022-2024年營收年比比較

主要企業簡介

Indivior PLC
Alkermes plc
Orexo AB
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
Camurus AB
Hikma Pharmaceuticals PLC
Titan Pharmaceuticals Inc.
Omeros Corporation
Mylan NV
Johnson & Johnson Services, Inc.
Boehringer Ingelheim GmbH
Purdue Pharma LP
ZLB Behring
Novartis AG
Mallinckrodt Pharmaceuticals
Sandoz
Gilead Sciences Inc.
ViiV Healthcare
Camurus AB

結論與建議

簡介目錄

Product Code: SQMIG35D2365

Global Opioid Use Disorder Market size was valued at USD 5.1 billion in 2023 and is poised to grow from USD 5.7 billion in 2024 to USD 13.92 billion by 2032, growing at a CAGR of 11.8% during the forecast period (2025-2032).

The growing prevalence of drug misuse, coupled with government initiatives aimed at raising awareness about opioid use disorder (OUD), is significantly driving market demand for OUD treatments. The rising rates of prescription opioid, heroin, and synthetic opioid misuse highlight the urgent need for effective treatment solutions. Increased focus from governments and public health organizations on OUD is creating long-term opportunities for market expansion. Enhanced awareness among the public, healthcare professionals, and stakeholders further supports this growth trajectory. Additionally, the improved infrastructure of treatment centers, outpatient clinics, telehealth services, and integrated care programs has made OUD care more accessible, driving revenue. However, challenges such as societal stigma, limited access to care in developing areas, high treatment costs, and regulatory complexities may restrict market penetration in the future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Opioid Use Disorder market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Opioid Use Disorder Market Segments Analysis

Global Opioid Use Disorder Market is segmented by Treatment, Route of Administration, Distribution Channel, End-User and region. Based on Treatment, the market is segmented into Methadone, Buprenorphine, Naltrexone and Other Therapies. Based on Route of Administration, the market is segmented into Oral, Injectable / Implant and Transdermal / Other. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online / E-commerce. Based on End-User, the market is segmented into Outpatient Clinics, Inpatient / Residential Treatment Centres and Remote Care. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Opioid Use Disorder Market

The Global Opioid Use Disorder market is being significantly bolstered by increased investments in research and development focused on new pharmacotherapy solutions. This influx of funding has led to the creation of innovative formulations that effectively address various opioid use disorders. Notable advancements include extended-release buprenorphine injections, implants, and novel antagonists such as naltrexone, as well as combination therapies that enhance treatment effectiveness. Additionally, these advanced drug formulations facilitate reduced dosing frequency, which in turn promotes better patient adherence to treatment. Collectively, these factors present promising opportunities for stakeholders in the opioid use disorder market.

Restraints in the Global Opioid Use Disorder Market

The Global Opioid Use Disorder market faces significant challenges due to the persistent social stigma surrounding the condition. Many individuals grapple with fears of judgment, discrimination, or legal repercussions, which deter them from seeking appropriate treatment options for opioid use disorder. Even when effective services are available, the utilization rates are often lower than desired because of cultural and societal barriers as well as feelings of internalized shame. These factors collectively hinder the progress and expansion of the market, as they prevent potential patients from accessing necessary care and support, ultimately impacting overall growth and development within the sector.

Market Trends of the Global Opioid Use Disorder Market

The global Opioid Use Disorder market is witnessing a significant shift towards long-acting and extended-release pharmacotherapies, driven by an increasing demand for effective treatment options. This trend encompasses the growing adoption of buprenorphine injections, naltrexone implants, and innovative combination therapies, which are gaining favor among clinicians for their enhanced efficacy and safety profiles. As these advanced formulations demonstrate improved patient compliance and reduced relapse rates, acceptance among patients is also on the rise, bolstering their prominence. This evolving landscape reflects a broader commitment to addressing opioid use disorder through more sustainable and efficient treatment modalities.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Assessment
Regulatory Landscape

Global Opioid Use Disorder Market Size by Treatment & CAGR (2025-2032)

Market Overview
Methadone
Buprenorphine
Naltrexone
Other Therapies

Global Opioid Use Disorder Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Oral
Injectable / Implant
Transdermal / Other

Global Opioid Use Disorder Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online / E-commerce

Global Opioid Use Disorder Market Size by End-User & CAGR (2025-2032)

Market Overview
Outpatient Clinics
Inpatient / Residential Treatment Centres
Remote Care

Global Opioid Use Disorder Market Size & CAGR (2025-2032)

North America (Treatment, Route of Administration, Distribution Channel, End-User)
- US
- Canada
Europe (Treatment, Route of Administration, Distribution Channel, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Treatment, Route of Administration, Distribution Channel, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Treatment, Route of Administration, Distribution Channel, End-User)
- Brazil
- Rest of Latin America
Middle East & Africa (Treatment, Route of Administration, Distribution Channel, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Indivior PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alkermes plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Orexo AB
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Camurus AB
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Titan Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Omeros Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Services, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Purdue Pharma L.P.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ZLB Behring
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mallinckrodt Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ViiV Healthcare
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Camurus AB
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments